Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). (Q39154824)

9 September 2017

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). (English)

1 reference

chronic lymphocytic leukemia

9 September 2017

0 references

0 references

1 reference

1 reference

10

Barbara Eichhorst

0 references

Valentin Goede

4

object named as

Valentin Goede

1 reference

9 September 2017

14

Michael Hallek

1 reference

9 September 2017

6

Jasmin Bahlo

1 reference

9 September 2017

1

Tait D Shanafelt

1 reference

9 September 2017

7

Timothy G Call

1 reference

9 September 2017

15

Susan L Slager

1 reference

9 September 2017

5

Kari G Chaffee

1 reference

9 September 2017

8

Susan M Schwager

1 reference

9 September 2017

16

Neil E Kay

1 reference

9 September 2017

Sameer A Parikh

2

1 reference

9 September 2017

Peter A Noseworthy

3

1 reference

9 September 2017

Wei Ding

9

1 reference

9 September 2017

Kirsten Fischer

11

1 reference

9 September 2017

Jose F Leis

12

1 reference

9 September 2017

Asher Alban Chanan-Khan

13

1 reference

9 September 2017

language of work or name

1 reference

25 November 2016

1 reference

9 September 2017

1 reference

9 September 2017

58

1 reference

9 September 2017

7

1 reference

9 September 2017

1630-1639

1 reference

Ibrutinib resistance in chronic lymphocytic leukemia

9 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Quality of life in patients with atrial fibrillation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Depression, anxiety, and quality of life in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The fiamingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Impact of atrial fibrillation on the risk of death: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Atrial fibrillation prevalence revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Lifetime risk for development of atrial fibrillation: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Validation of an atrial fibrillation risk algorithm in whites and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1257795

10.1080/10428194.2016.1257795

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference